hiv 1

Summary

Summary: The type species of LENTIVIRUS and the etiologic agent of AIDS (ACQUIRED IMMUNODEFICIENCY SYNDROME). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.

Top Publications

  1. doi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
  2. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
  3. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  4. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
  5. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
  6. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
  7. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  8. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
  9. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
  10. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005

Research Grants

  1. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
  2. The mechanisms by which alcohol and HIV render the lung susceptible to injury
    DAVID MARSHALL GUIDOT; Fiscal Year: 2011
  3. The Vaginal Microbiome: Disease, Genetics and the Environment
    Gregory Buck; Fiscal Year: 2009
  4. The Vaginal Microbiome: Disease, Genetics and the Environment
    GREGORY ALLEN BUCK; Fiscal Year: 2010
  5. Pharmacology of Antiretroviral Nanoparticle Micelles
    Christopher J Destache; Fiscal Year: 2010
  6. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2009
  7. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2010
  8. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
  9. Tat Transactivation
    BORIS PETERLIN; Fiscal Year: 2009
  10. Tat Transactivation
    BORIS PETERLIN; Fiscal Year: 2006

Detail Information

Publications306 found, 100 shown here

  1. doi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
    ..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
  2. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
    ..Vpu co-localized with CD317 and inhibited these effects. Inhibition of Vpu function and consequent mobilization of tetherin's antiviral activity is a potential therapeutic strategy in HIV/AIDS...
  3. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  4. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  5. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    ..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
  6. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    ..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
  7. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  8. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    ....
  9. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  10. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  11. pmc Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  12. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  13. pmc Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing
    Jesus F Salazar-Gonzalez
    Department of Medicine, University of Alabama at Birmingham, 720 20th Street South, Kaul 816, Birmingham, AL 35294, USA
    J Virol 82:3952-70. 2008
    ....
  14. pmc Tetherin inhibits HIV-1 release by directly tethering virions to cells
    David Perez-Caballero
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 139:499-511. 2009
    ....
  15. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays...
  16. ncbi HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
    Y Feng
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases NIAID, NIH, Bethesda, MD 20892, USA
    Science 272:872-7. 1996
    ..Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophagetropic HIV-1 isolates...
  17. pmc The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    Nilu Goonetilleke
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
    J Exp Med 206:1253-72. 2009
    ..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
  18. pmc Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    ..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
  19. pmc Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    PLoS ONE 5:e8805. 2010
    ....
  20. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  21. pmc Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking
    Richard S Mitchell
    Department of Medicine, University of California San Diego, La Jolla, CA, USA
    PLoS Pathog 5:e1000450. 2009
    ..Together, the data support a model in which Vpu co-opts the beta-TrCP/SCF E3 ubiquitin ligase complex to induce endosomal trafficking events that remove BST-2 from its site of action as a virion-tethering factor...
  22. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
    ..The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization...
  23. ncbi Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
    R Liu
    Aaron Diamond AIDS Research Center, Rockefeller University New York, New York 10016, USA
    Cell 86:367-77. 1996
    ..These findings indicate the importance of CKR-5 in HIV-1 transmission and suggest that targeting the HIV-1-CKR-5 interaction may provide a means of preventing or slowing disease progression...
  24. pmc Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
    Jorge R Almeida
    Cellular Immunology Laboratory, U543, Institut National de la Sante et de la Recherche Medicale, Avenir Group, 75013 Paris, France
    J Exp Med 204:2473-85. 2007
    ..Such attributes are interlinked and constitute the basis for effective control of HIV-1 replication. These data on the features of effective CD8+ T cells in HIV infection may aid in the development of successful T cell vaccines...
  25. pmc Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains
    Daniel Sauter
    Institute of Molecular Virology, Universitatsklinikum, 89081 Ulm, Germany
    Cell Host Microbe 6:409-21. 2009
    ..This may explain why group M viruses are almost entirely responsible for the global HIV/AIDS pandemic...
  26. pmc A whole-genome association study of major determinants for host control of HIV-1
    Jacques Fellay
    Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Science 317:944-7. 2007
    ..These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents...
  27. ncbi Pathways to neuronal injury and apoptosis in HIV-associated dementia
    M Kaul
    Center for Neuroscience and Aging Research, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA
    Nature 410:988-94. 2001
    ..Recent advances in understanding the signalling pathways mediating these events offer hope for therapeutic intervention...
  28. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  29. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  30. pmc Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor
    Matthew Stremlau
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School Division of AIDS, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:5514-9. 2006
    ..Inhibiting the proteasome did not abrogate restriction. Thus, TRIM5alpha restricts retroviral infection by specifically recognizing the capsid and promoting its rapid, premature disassembly...
  31. pmc Molecular architecture of native HIV-1 gp120 trimers
    Jun Liu
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Nature 455:109-13. 2008
    ..Our findings elucidate the structure and conformational changes of trimeric HIV-1 gp120 relevant to antibody neutralization and attachment to target cells...
  32. pmc Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  33. doi HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor
    Christine Goffinet
    Department of Virology, University of Heidelberg, Heidelberg, Germany
    Cell Host Microbe 5:285-97. 2009
    ..Thus, HIV-1 Vpu suppresses the expression of the CD317 antiviral factor in human cells, and the species-specific resistance to this suppression may guide the development of small animal models of HIV infection...
  34. pmc Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2
    Bin Jia
    Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, Southborough, MA, USA
    PLoS Pathog 5:e1000429. 2009
    ....
  35. doi Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission
    Stefanie Sowinski
    Division of Cell and Molecular Biology, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ, UK
    Nat Cell Biol 10:211-9. 2008
    ..These data lead us to propose that HIV-1 can spread using nanotubular connections formed by short-term intercellular unions in which T cells specialize...
  36. ncbi Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
    Ann M Sheehy
    Department of Microbiology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 418:646-50. 2002
    ..Because the Vif:CEM15 regulatory circuit is critical for HIV-1 replication, perturbing the circuit may be a promising target for future HIV/AIDS therapies...
  37. ncbi The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
    Matthew Stremlau
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 427:848-53. 2004
    ..Our studies identify TRIM5alpha as a species-specific mediator of innate cellular resistance to HIV-1 and reveal host cell components that modulate the uncoating of a retroviral capsid...
  38. pmc Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
    Bertran Auvert
    Hopital Ambroise Pare, Assitance Publique Hôpitaux de Paris, Boulogne, France
    PLoS Med 2:e298. 2005
    ..Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled intervention trial was conducted in a general population of South Africa to test this hypothesis...
  39. pmc Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, Washington 98109, USA
    J Virol 83:757-69. 2009
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action...
  40. pmc Rapid evolution of the neutralizing antibody response to HIV type 1 infection
    Douglas D Richman
    Department of Pathology, Veterans Affairs San Diego Healthcare System and the University of California at San Diego, La Jolla, CA 92093 0679, USA
    Proc Natl Acad Sci U S A 100:4144-9. 2003
    ..These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection...
  41. doi Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
    Florencia Pereyra
    Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02129, USA
    J Infect Dis 197:563-71. 2008
    ..The mechanisms behind this outcome remain largely unknown, and a better understanding of them will likely influence future vaccine strategies...
  42. ncbi HIV-1 accessory proteins--ensuring viral survival in a hostile environment
    Michael H Malim
    Department of Infectious Diseases, King s College London School of Medicine, 2nd Floor, Borough Wing, Guy s Hospital, London Bridge, London, SE1 9RT, UK
    Cell Host Microbe 3:388-98. 2008
    ..Broadly speaking, the HIV-1 accessory proteins modify the local environment within infected cells to ensure viral persistence, replication, dissemination, and transmission...
  43. pmc Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    Richard E Haaland
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
    PLoS Pathog 5:e1000274. 2009
    ....
  44. pmc Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Exp Med 200:761-70. 2004
    ..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical...
  45. pmc Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 94:13193-7. 1997
    ..In addition, the presence of unintegrated HIV-1 DNA in infected resting CD4+ T cells from patients receiving HAART, even those with undetectable plasma viremia, suggests persistent active virus replication in vivo...
  46. pmc High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states
    Kevin A Wilkinson
    Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina, United States of America
    PLoS Biol 6:e96. 2008
    ..High-throughput SHAPE reveals a comprehensive view of HIV-1 RNA genome structure, and further application of this technology will make possible newly informative analysis of any RNA in a cellular transcriptome...
  47. pmc Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    J R Mascola
    Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation, Rockville, Maryland 20850, USA
    J Virol 73:4009-18. 1999
    ..These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease...
  48. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
    ..The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels...
  49. doi Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation
    Gero Hütter
    Department of Hematology, Oncology, and Transfusion Medicine, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Germany
    N Engl J Med 360:692-8. 2009
    ..The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection...
  50. pmc HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse
    Clare Jolly
    The Sir William Dunn School of Pathology, University of Oxford, UK
    J Exp Med 199:283-93. 2004
    ..We propose that receptor engagement by Env directs the rapid, actin-dependent recruitment of HIV receptors and adhesion molecules to the interface, resulting in a stable adhesive junction across which HIV infects the target cell...
  51. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  52. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  53. pmc Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing
    Céline Marban
    INSERM unité 575 Pathophysiology of Nervous System, Centre de Neurochimie, Strasbourg, France
    EMBO J 26:412-23. 2007
    ..Altogether, our findings uncover new therapeutic opportunities for purging latent HIV-1 viruses from their cellular reservoirs...
  54. ncbi The neuropathogenesis of AIDS
    Francisco González-Scarano
    Department of Neurology, 3 West Gates, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Philadelphia 19104 4283, USA
    Nat Rev Immunol 5:69-81. 2005
    ..Here, we discuss the studies that are being carried out to determine the respective contributions of infection, and monocyte and macrophage activation, to disease progression...
  55. pmc Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection
    Xu Wang
    Division of Allergy and Immunology, Joseph Stokes Jr Research Institute at The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 113:671-4. 2009
    ..These findings provide compelling and direct evidence at the molecular level to support the notion that intracellular anti-HIV-1 miRNA-mediated innate immunity may have a key role in protecting monocytes/macrophages from HIV-1 infection...
  56. ncbi Persistent immune activation in HIV-1 infection is associated with progression to AIDS
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research at CLB, Tropical Medicine and AIDS, Amsterdam, The Netherlands
    AIDS 17:1881-8. 2003
    ..HIV-1 infection is characterized by chronic generalized CD8 and CD4 T cell hyperactivation, the biological effect of which is not understood...
  57. ncbi HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
    T Dragic
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York 10016, USA
    Nature 381:667-73. 1996
    ..CC-CKR-5 is a second receptor for NSI primary viruses...
  58. pmc New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Clin Microbiol 41:4531-6. 2003
    ....
  59. ncbi Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
    Janet D Siliciano
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205 USA
    Nat Med 9:727-8. 2003
    ..Here we show that even in treated patients who have had no detectable viremia for as long as 7 years, the reservoir decays so slowly (t(1/2) = 44 months) that eradication is unlikely...
  60. pmc Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    J B Dinoso
    Departmentsof Medicine and Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 106:9403-8. 2009
    ..Our results suggest that residual viremia is not the product of ongoing, complete cycles of viral replication, but rather of virus output from stable reservoirs of infection...
  61. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  62. ncbi Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4
    Zhiyuan Yang
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720, USA
    Mol Cell 19:535-45. 2005
    ..Brd4, HEXIM1, and 7SK are all implicated in regulating cell growth, which may result from their dynamic control of the general transcription factor P-TEFb...
  63. ncbi Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda
    Maria J Wawer
    Heilbrun Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, New York 10032, USA
    J Infect Dis 191:1403-9. 2005
    ..We estimated rates of human immunodeficiency virus (HIV)-1 transmission per coital act in HIV-discordant couples by stage of infection in the index partner...
  64. ncbi Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission
    Ellen R Cooper
    Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston University School of Medicine, 774 Albany Street, Suite 506, Boston, MA 02118, U S A
    J Acquir Immune Defic Syndr 29:484-94. 2002
    ..The Women and Infants Transmission Study is a prospective natural history study that has been enrolling HIV-1-infected pregnant women and their infants since 1989...
  65. ncbi Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa
    Laith J Abu-Raddad
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Science 314:1603-6. 2006
    ..Hence, transient and repeated increases in HIV viral load resulting from recurrent co-infection with malaria may be an important factor in promoting the spread of HIV in sub-Saharan Africa...
  66. pmc Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
    Stephen A Migueles
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 29:1009-21. 2008
    ..They also demonstrate that lytic granule contents of memory cells are a critical determinant of cytotoxicity that must be induced for maximal per-cell killing capacity...
  67. pmc TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing
    Astrid D Haase
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4508 Basel, Switzerland
    EMBO Rep 6:961-7. 2005
    ..The TRBP-Dicer interaction shown raises interesting questions about the potential interplay between RNAi and interferon-PKR pathways...
  68. pmc HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation
    Bastien Mangeat
    Department of Dermatology and Venereology, University Hospitals and Medical School of Geneva, University of Geneva, Switzerland
    PLoS Pathog 5:e1000574. 2009
    ..Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication...
  69. ncbi Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    ..We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings...
  70. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  71. pmc The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  72. ncbi Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery
    Jez G Carlton
    Department of Infectious Diseases, King s College London School of Medicine, London, UK
    Science 316:1908-12. 2007
    ..Thus, HIV-1 budding and cytokinesis use a similar subset of cellular components to carry out topologically similar membrane fission events...
  73. pmc Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy
    Moraima Guadalupe
    Department of Medical Microbiology and Immunology, University of California, Davis, California 95616, USA
    J Virol 77:11708-17. 2003
    ..Monitoring of the restoration and/or maintenance of CD4(+) T cells in GALT provides a more accurate assessment of the efficacy of antiviral host immune responses as well as HAART...
  74. ncbi The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
    G B Cohen
    Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA
    Immunity 10:661-71. 1999
    ..These results suggest that subpopulations of CTL and NK cells may be uniquely suited for combating HIV...
  75. pmc Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    ..This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies...
  76. ncbi The stoichiometry of Gag protein in HIV-1
    John A G Briggs
    Division of Structural Biology, The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7BN, UK
    Nat Struct Mol Biol 11:672-5. 2004
    ..In the immature virus, Gag forms a hexameric lattice with a spacing of 8.0 nm. Thus, less than half of the CA proteins form the mature core...
  77. pmc Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    Patrick Dorr
    Discovery Biology, Pfizer Global Research and Development Sandwich Laboratories, Kent CT13 9NJ, United Kingdom
    Antimicrob Agents Chemother 49:4721-32. 2005
    ..Clinical trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS...
  78. pmc Adaptation of HIV-1 to human leukocyte antigen class I
    Yuka Kawashima
    Division of Viral Immunology, Center for AIDS Research, Kumamoto University, 2 2 1 Honjo, Kumamoto 860 0811, Japan
    Nature 458:641-5. 2009
    ....
  79. pmc A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication
    Man Lung Yeung
    Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892 0460, USA
    J Biol Chem 284:19463-73. 2009
    ..We discuss the similarities and differences between our shRNA findings for HIV-1 using a spreading infection assay in human Jurkat T-cells and results from other investigators who used siRNA-based screenings in HeLa or 293T cells...
  80. pmc Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion
    Ravindra K Gupta
    Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, United Kingdom
    PLoS Pathog 5:e1000443. 2009
    ..This work suggests that tetherin binding agents might protect it from viral encoded countermeasures and thus make powerful antivirals...
  81. pmc Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
    ..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
  82. pmc Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants
    M R Abrahams
    Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa
    J Virol 83:3556-67. 2009
    ....
  83. pmc Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
  84. ncbi Identification of a major co-receptor for primary isolates of HIV-1
    H Deng
    Skirball Institute for Biomolecular Medicine, New York University Medical Center, 10016, USA
    Nature 381:661-6. 1996
    ..The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1alpha and MIP-1beta...
  85. pmc HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
    Asier Saez-Cirion
    Unité de Régulation des Infections Rétrovirales, Institut Pasteur, 75725 Paris, France
    Proc Natl Acad Sci U S A 104:6776-81. 2007
    ..This constitutive antiviral capacity of CD8(+) T cells could account for the control of viral replication in HIC...
  86. pmc Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 317:1930-4. 2007
    ....
  87. pmc Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations
    Gabriella Rozera
    Laboratory of Virology, INMI L, Spallanzani, Rome, Italy
    Retrovirology 6:15. 2009
    ..V3 amino acid sequences were used to establish heterogeneity parameters, to build phylogenetic trees and to predict co-receptor usage...
  88. ncbi New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
    R S Janssen
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 280:42-8. 1998
    ..Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention...
  89. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  90. ncbi A quantitative assay for HIV DNA integration in vivo
    S L Butler
    Infectious Disease Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA
    Nat Med 7:631-4. 2001
    ..The integration assay employs a novel quantitative form of Alu-PCR that should be generally applicable to studies of integrating viruses and gene transfer vectors...
  91. pmc Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
    E S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 81:6187-96. 2007
    ..These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection...
  92. ncbi Distribution and three-dimensional structure of AIDS virus envelope spikes
    Ping Zhu
    Department of Biological Science and Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida 32306, USA
    Nature 441:847-52. 2006
    ..Reconciling available atomic structures with the three-dimensional whole spike density map yields insights into the orientation of Env spike structural elements and possible structural bases of their functions...
  93. pmc Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration
    Jean L Mbisa
    HIV Drug Resistance Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Virol 81:7099-110. 2007
    ..These novel observations suggest that HIV-1 cDNA produced in the presence of A3G exhibits defects in primer tRNA processing, plus-strand DNA transfer, and integration...
  94. pmc HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes
    Kosuke Miyauchi
    Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Cell 137:433-44. 2009
    ..These findings imply that HIV-1 infects cells via endocytosis and envelope glycoprotein- and dynamin-dependent fusion with intracellular compartments...
  95. ncbi Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK
    Lancet 352:1725-30. 1998
    ..We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens...
  96. pmc Analysis of the interaction of primate retroviruses with the human RNA interference machinery
    Jennifer Lin
    Center for Virology, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 81:12218-26. 2007
    ..Together, these data argue that HIV-1 and HTLV-1 neither induce the production of viral small interfering RNAs or microRNAs nor repress the cellular RNA interference machinery in infected cells...
  97. pmc Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  98. pmc HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes
    Yukie Iwabu
    Department of Pathology, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    J Biol Chem 284:35060-72. 2009
    ..Also, we propose the following configuration of BST-2 in tethering virions to the cell surface; each of the dimerized BST-2 molecules acts as a bridge between viral and cell membranes...
  99. pmc Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion
    Eri Miyagi
    Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Proc Natl Acad Sci U S A 106:2868-73. 2009
    ....
  100. doi Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02)
    Sophie Limou
    Conservatoire National des Arts et Metiers, Universite Paris 7, Paris, France
    J Infect Dis 199:419-26. 2009
    ..The present study, the first GWAS of HIV-1 nonprogressors, underscores the potential for some HLA genes to control disease progression soon after infection...
  101. doi Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Leonidas Stamatatos
    1Seattle Biomedical Research Institute, Seattle, Washington, USA
    Nat Med 15:866-70. 2009
    ..A concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV-1...

Research Grants82

  1. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
  2. The mechanisms by which alcohol and HIV render the lung susceptible to injury
    DAVID MARSHALL GUIDOT; Fiscal Year: 2011
    ..This research project is designed to determine how alcohol and HIV-1 interact to make the lung susceptible to injury, and to develop effective treatments that can improve the health of these vulnerable individuals. ..
  3. The Vaginal Microbiome: Disease, Genetics and the Environment
    Gregory Buck; Fiscal Year: 2009
    ....
  4. The Vaginal Microbiome: Disease, Genetics and the Environment
    GREGORY ALLEN BUCK; Fiscal Year: 2010
    ..abstract_text> ..
  5. Pharmacology of Antiretroviral Nanoparticle Micelles
    Christopher J Destache; Fiscal Year: 2010
    ..Due to the nanoparticle small size, the particles will stay in tissue longer and allow for less frequent dosing. This nanoparticle delivery system could affect the future of HIV- 1 treatment. ..
  6. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2009
    ..The new knowledge we expect to draw from these studies could lead to the design of new therapies aimed at the pool of latently infected cells, and to virus eradication. ..
  7. A New Insight into HIV-1 Latency Through a Novel in Vitro System
    Fabio Romerio; Fiscal Year: 2010
    ..The new knowledge we expect to draw from these studies could lead to the design of new therapies aimed at the pool of latently infected cells, and to virus eradication. ..
  8. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
  9. Tat Transactivation
    BORIS PETERLIN; Fiscal Year: 2009
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
  10. Tat Transactivation
    BORIS PETERLIN; Fiscal Year: 2006
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. [unreadable] [unreadable]..
  11. Tat Transactivation
    B Matija Peterlin; Fiscal Year: 2007
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. [unreadable] [unreadable]..
  12. Recombinase Polymerase Amplification for Point-of-Care Diagnosis of Infant HIV-1
    DAVID SCOTT BOYLE; Fiscal Year: 2011
    ..This proposal describes several nascent technologies that can be used to develop a rapid and easy-to-use HIV-1 diagnostic tool for use at the point of care in low-resource settings. ..
  13. Establishment fo HIV infection in cotton rats
    Jorge Blanco; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  14. HIV evolution and CD16+ monocytes as cellular reservoirs: insights into HIV/pulmo
    Sharilyn Almodovar; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: This project seeks to fingerprint the HIV in the lungs of infected patients and to discover how HIV proteins insults the endothelial cells in the lung vasculature. (End of Abstract) ..
  15. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2000
    ....
  16. TARGETED CELLULAR KILLING OF HIV AND HIV-INFECTED CELLS
    MICHAEL FANGER; Fiscal Year: 1993
    ....
  17. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2001
    ....
  18. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 1999
    ....
  19. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2001
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  20. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2003
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  21. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2000
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  22. Improving Antibodies to Virion Based HIV Vaccines
    Kathie Grovit Ferbas; Fiscal Year: 2009
    ....
  23. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2002
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  24. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2004
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  25. Predictive QSAR Modeling of HIV-1 Integrase Inhibitors
    Rajni Garg; Fiscal Year: 2009
    ..The goal of this project is to understand the interactions between the HIV-1 integrase enzyme and its inhibitors that will help in the design of new drugs active against drug-resistant HIV-1. ..
  26. Structure and Function of Ribonucleoprotein Complexes Modulating HIV Replication
    Tariq M Rana; Fiscal Year: 2010
    ..These results would also be valuable in developing new strategies for blocking the expression of retroviral or other disease- related genes. ..
  27. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2004
    ..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
  28. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2007
    ..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
  29. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2005
    ..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
  30. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2006
    ..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
  31. Generating SEVI disaggregases to prevent HIV infection
    JAMES GORDON SHORTER; Fiscal Year: 2012
    ..Realization of our objectives will empower urgently needed new strategies to prevent HIV-1 infection and combat the global HIV/AIDS pandemic. ..
  32. MURINE MODEL OF HIV INFECTION OF HUMAN BRAIN
    Cristian Achim; Fiscal Year: 1999
    ....
  33. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2005
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  34. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2007
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  35. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2006
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  36. Methamphetamine, HIV, Neuroinflammation and Behavior
    Rodney Johnson; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  37. SIV PATHOGENESIS DURING ONTOGENY
    Ruth Ruprecht; Fiscal Year: 1991
    ..Our proposed experiments may yield important information for planning clinical trials aimed at preventing maternal HIV-1 transmission...
  38. Targeting Viral Envelope Glycoproteins with Synthetic Antibodies
    Jonathan Lai; Fiscal Year: 2010
    ..We are using this new technology to identify novel antibodies against viral targets. This work will provide new tools to understand viral infection and how this process can be inhibited by therapeutic agents or vaccines. ..
  39. IMMUNITY TO PNEUMOCOCCUS IN PERSONS WITH HIV
    Edward Janoff; Fiscal Year: 1991
    ..These data may suggest strategies to prevent and more effectively treat these serious infections, and to identify patients at particularly high risk...
  40. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2009
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  41. HIV: GENDER AND SEX HORMONE EFFECTS ON T CELL KINETICS
    Marc Hellerstein; Fiscal Year: 2001
    ..and whether T cell turnover tracks better with CD4 count than VL in women, compared to men...
  42. IN VITRO ANTI-HIV1 CAP ACTIVITY
    Shibo Jiang; Fiscal Year: 2001
    ..The goal of the proposed research is the rigorous and comprehensive pre-clinical evaluation of CAP and its formulations in order to expedite its transfer into human clinical trials. ..
  43. The Role of Lipid Rafts in Vpu Function
    EDWARD BRICE STEPHENS; Fiscal Year: 2010
    ..The information gained from these studies may result in novel antiviral strategies against HIV-1. ..
  44. High Specificity HIV-1 Markers Predictive of Neuro-AIDS
    Brian Wigdahl; Fiscal Year: 2010
    ....
  45. HIV INFECTION AMONG INTRAVENOUS DRUG USERS
    Michael Marmor; Fiscal Year: 1991
    ....
  46. HIV-1 ENV PROTEINS--TARGETS FOR ANTIVIRAL CHEMOTHERAPY
    A Robert Neurath; Fiscal Year: 1993
    ..Accomplishment of these goals is expected to lead to improved combined therapy, and possibly prophylaxis of HIV-1 infections...
  47. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2005
    ....
  48. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2007
    ....
  49. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2007
    ....
  50. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2006
    ....
  51. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2004
    ....
  52. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2004
    ..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
  53. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2003
    ..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
  54. HERPESVIRUS ASSOCIATED DEMYELINATING ENCEPHALOMYELITIS IN JAPANESE MACAQUES
    Michael Axthelm; Fiscal Year: 2000
    ..The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med 188(6):1159-1171, 1998. ..
  55. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2001
    ..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
  56. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2002
    ..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
  57. ALVEOLAR MACROPHAGES AND DEFENSE OF THE LUNG IN AIDS
    Paul Luciw; Fiscal Year: 1990
    ..With respect to pathogenesis, results of these investigations may reveal whether viral infection directly disrupts AM and PBMM or whether indirect mechanisms lead to cellular dysfunctions...
  58. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1990
    ..The proposed studies could constitute a step towards the formulation of effective and highly immunogenic synthetic vaccines against AIDS and other infectious diseases...
  59. MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYS
    Karin Musier Forsyth; Fiscal Year: 1999
    ..c) Stopped-flow fluorescence techniques will be used to investigate the kinetic mechanism of NC unwinding and annealing of tRNALys,3. ..
  60. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1991
    ..The proposed studies could constitute a step towards the formulation of effective and highly immunogenic synthetic vaccines against AIDS and other infectious diseases...
  61. MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYS
    Karin Musier Forsyth; Fiscal Year: 2000
    ..c) Stopped-flow fluorescence techniques will be used to investigate the kinetic mechanism of NC unwinding and annealing of tRNALys,3. ..
  62. MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYS
    Karin Musier Forsyth; Fiscal Year: 2001
    ..c) Stopped-flow fluorescence techniques will be used to investigate the kinetic mechanism of NC unwinding and annealing of tRNALys,3. ..
  63. Cellular and molecular mechanisms of gp120 neurotoxicity
    Italo Mocchetti; Fiscal Year: 2011
    ..These phenomena are blocked by inhibitors of axonal transport. Therefore, we propose to explore the hypothesis that axonal transport of gp120 is an intracellular mechanism crucial for its neurotoxic effect. ..
  64. CORECEPTOR USAGE AND HIV DISEASE KINETICS
    Donald Mosier; Fiscal Year: 1999
    ..Finally, we will use T cells lines form CCR5 32/32 individuals transfected with CCR5 or CMV US28 constructs to generate isogeneic lines differing in co-receptor expression to determine if direct infection is required for cell death. ..
  65. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2004
    ..abstract_text> ..
  66. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2003
    ..abstract_text> ..
  67. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2005
    ..abstract_text> ..
  68. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2001
    ..abstract_text> ..
  69. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2002
    ..abstract_text> ..
  70. Structural determinants of HIV-1 5'-UTR riboswitch and NC actuation by MS3D
    Daniele Fabris; Fiscal Year: 2006
    ....
  71. HIV/TB in Uganda: Punctuated Antiretroviral Therapy
    Christopher Whalen; Fiscal Year: 2006
    ..abstract_text> ..
  72. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2002
    ....
  73. HIV-1 chemoprophylaxis and archived drug resistance in infants
    Deborah Persaud; Fiscal Year: 2007
    ....